Strengthening its commitment to oncology, Novartis has signed a license and asset purchase agreement with Arvinas to develop and commercialise ARV-766 and purchase Arvinas’ preclinical AR-V7 programme. Through the deal, which includes a US$150 M upfront payment as well as up to US$1.01 B in milestones, Novartis gains worldwide rights to ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor degrader for patients with prostate cancer. The deal highlights Novartis’ commitment to expanding its own prostate cancer portfolio, as it prepares to file its radiotherapy, Pluvicto, for approval in earlier lines of therapy.